Zusammenfassung
Seit der Einführung von Melphalan und Cyclophosphamid in die Behandlung des multiplen Myeloms konnten wesentliche Verbesserungen der zytostatischen und supportiven Therapie erreicht werden. Trotzdem sind die mit diesen konventionellen Behandlungsmaßnahmen erreichbaren mittleren Überlebenszeiten von 20–32 Monaten nach wie vor unbefriedigend [1], Dies mag mit ein Grund gewesen sein, warum die ersten Fallberichte über eine erfolgreiche Behandlung von Myelompatienten mit Interferon besonderen Optimismus auslöste. 1979 berichteten Ideström und Ma. [2] über einen gegenüber Melphalanresistenten Patienten, der unter Behandlung mit 3–6 x 106 U Leukozyteninterferon eine deutliche Reduktion seines Tumors erreichte. In einem weiteren, im selben Jahr veröffentlichten Bericht [3] wurden 4 bereits chemotherapieresistente Patienten beschrieben, die alle auf eine Interferonbehandlung angesprochen hatten, wobei 2 dieser Patienten sogar eine komplette Remission erreichten. In einer nachfolgenden größer angelegten Studie erzielte dieselbe Arbeitsgruppe jedoch mit einer Gesamtansprechrate von 14% weit weniger eindrucksvolle Resultate.
Unterstützt durch den Fonds zur Förderung zur wissenschaftlichen Forschung Österreichs, P 4999, und das Ludwig Boltzmann-Institut für Gerontologie
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Ludwig H (1982) Multiples Myelom. Diagnose, Klinik und Therapie. Berlin-Heidelberg-New York: Springer
Ideström K, Cantell K, Killander D, Nilsson K, Strander H, Willems J (1979) Interferon therapy in multiple myeloma. Acta Med Scand 205: 149–154
Mellstedt H, Ahre A, Björkholm M, Holm G, Johansson B, Strander H (1979) Interferon therapy in myelomatosis. Lancet i: 245–248
Guttermann JU, Blumenschein GR, Alexanian R, Hweeyoung Y, Buzdar AU, Cabanillas F, Hortobagyi GN, et al. (1980) Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93: 399–406
Alexanian R, Guttermann J, Levy H (1982) Interferon treatment for multiple myeloma. In Salmon, SE (ed.): Clinics in Haematology. London-Philadelphia-Toronto: Saunders, pp 211–220
Ludwig H, Swetly P (1980) In vitro inhibitory effect of interferon on multiple myeloma stem cells. Cancer Immunol Immunther 9: 139–143
Brenning G, Ahre A, Nilsson K (1985) Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 5: 543–549
Brenning G (1985) The in vitro effect of leukocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 35: 178–185
Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Guttermann JU (1986) Treatment of multiple myeloma with recombinant alpha-interferon. Blood 67: 275–278
Welander CE (1987) Overview of preclinical and clinical studies of interferon alpha-2b in combination with cytotoxic drugs. Invest N Drugs Suppl 5: 47–59
Aapro MS, Alberts DS, Salmon SE (1983) Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10: 161–166
Ahre A, Björkholm M, Mellstedt H, Brenning G, Engstedt L, Gahrton G, Gyllenhammar H, et al (1984) Human leukocyte interferon and intermittent high dose melphalan/ prednisone administration in the treatment of multiple myeloma. A randomized clinical trial. Cancer Treat Rep 68: 1331–1338
Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, et al. (1984) Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 77: 427–432
Costanzi JJ, Cooper R, Scarffe JH, Ozer H, Grubbs SS, Ferresi RW, Pollard R, et al. (1985) Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 3: 645–659
Wagstaff J, Loynds P, Scarffe JH (1985) Phase II study of rDNA human alpha-2 inter¬feron in multiple myeloma. Cancer Treat Rep 69: 495–498
Takaku F (1985) Phase II study of interferon alpha-2 (Sch 30500) for hematopoietic tumors. Rinsyo Iyaku, 1: 59–68
Ludwig H, Cortelezzi A, Scheithauer W, Van Camp BGK, Kuzmits R, Fillet G, Peetermans M, et al. (1986) Recombinant interferon alpha-2C versus polychemotherapy ( VMCP) for treatment of multiple myeloma: A prospective randomized trial. Eur J Cancer Clin Oncol 22: 1111–1116
Ohno R, Kimura K (1986) Treatment of multiple myeloma with recombinant interferon alpha-2a. Cancer 57: 1685–1688
Kimura K (1984) A cooperative phase I-II study of HLBI in patients with malignant tumors. Jap J Cancer Chemother 11: 1324–1331
Rodrigez MA, Prinz WA, Sibbit WC, Bankhurst AD, Williams RC (1983) Alpha-interferon increases immunoglobulin production in cultured human mononuclear leukocytes. J Immunol 130: 1215–1219
Cooper MR, Fefer A, Thompson J, Case DC, Kempf R, Sacher R, Neefe J, et al (1986) Alpha-2 interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: A phase I-II trial. Cancer Treat Rep 70: 473–476
Case DC, Fefer A, Thompson J, Cooper MR, Bonnern EM (1985) Alpha-2 interferon (Intron A) and adriamycin in the treatment of relapsing/refractory multiple myeloma. New Orleans: Proc Am Soc Hematol p. 213
Ludwig H, Cortelezzi A, Fritz E, Kührer I, Polli E, Scheithauer W, Flener R (1987) Combined interferon-polychemotherapy versus polychemotherapy in multiple myeloma: A phase-Ill study. In: Cantell K, Schellekens H (eds): The Biology of the Interferon System. Dordrecht-Boston-Lancaster: Martinus Nijhoff Publishers, pp. 363–370
Österborg A, Björkholm M, Gahrton G, Grimfors G, Gyllenhammar H, Hast R, Holm G, et al. (1987) Melphalan/prednisone (MP) therapy vs melphalan/prednisone + human alpha-interferon (MP/IFN) therapy in patients with multiple myeloma, stage II and III. A randomized study from the Myeloma Group of Central Sweden (MGCS). An interimistic report. Stockholm: Proc Ann Meet Swed Med Soc, p. 169
Oken MM, Kyle RA, Greipp PR, Kay NE, O’Connel T, O’Connel MJ (1988) Alternating cycles of VMCP with interferon (rIFN-alpha2) in the treatment of multiple myeloma. Proc ASCO 7: 225
Mandelli F, Tribalto M, Cantonetti M, Petrucci MT, Boccadoro M, Pijeri A, Marmount F, et al. (1987) Recombinant alpha 2b interferon as maintenance therapy in responding multiple myeloma patients M84 protocol. Report of the Italian Multiple Myeloma Study Group. (Preliminary results). 4th Eur Conf clin Oncol (ECCO), Madrid, Nov. 1–4
Ohno R (1987) Interferons in the treatment of multiple myeloma. Int J Cancer Suppl 1: 14–20
Furue H (1985) Phase II clinical study on interferon-alfa, produced from human lymphoblast (Interferon-alfa), for malignant tumor. Rinsho Iyaku 1: 1103–1121
Tsubura E (1986) The phase I and early phase II studies of human lymphoblast interferon (MOR-22) in the treatment of malignant tumors. J Jap Soc Cancer Ther 21: 1049–1058
Billiau A, Bioemmen J, Bogaerts M, Claeys H, Van Damme J, De Ley M, De Somer P, et al. (1981) Interferon therapy in multiple myeloma: Failure of human fibroblast interferon administration to alter the course of light chain disease. Eur J Cancer 17: 875–882
Ezaki K, Ogawa M, Okabe K, Abe K, Inove K, Horikoshi N, Inagaki J (1982) Clinical and immunological studies of human fibroblast interferon. Cancer Chemother Pharmacol 8: 47–55
Misset JL, Mathe G, Gastiaburn H, Goutner A, Dorval T, Gouveia J, Hayat J, et al (1982) Treatment of lymphoid neoplasia by interferon. I. Human fibroblastic interferon (beta) in malignant gammapathies phase II trial. Anticancer Res 2: 63–66
Fossa SD (1987) Improved subjective tolerability of interferon by combination with prednisolone. Eur J Cancer Clin Oncol 23: 875–876
Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, Osborne JR, et al (1987) Multiple myeloma treated with high dose intravenous melphalan. Brit J Haematol 66: 55–62
Croghan M, Durie B, Vela E, Dalton W, Tu F (1987) Paradoxic increased sensitivity of chemotherapy resistant myeloma cells to the biologic agents TNF-alpha, TNF-beta, IFN-alpha 2B plus corticosteroids. Proc Am Meet Am Ass Cancer Res 28: 404
Brenning G, Jernberg H, Gidlund M, Sjoeberg O, Nilsson K (1986) The effect of alpha and gamma-interferon on proliferation and production of IgE and beta 2-microglobulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline. Scand J Haematol 37: 280–288
Kurschel E, Metz-Kurschel U, Hofmann W, Niederle N (1987) Untersuchungen zur Erfassung der Nephrotoxizität von humanem alpha-2b-Interferon unter Berücksichtigung der Analyse von Harnenzymen bei Patienten mit chronischer myeloischer Leukämie. Klin Wschr 65: 667–672
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ludwig, H. (1990). Interferon in der Behandlung des multiplen Myeloms. In: Niederle, N., von Wussow, P. (eds) Interferone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93383-7_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-93383-7_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-93384-4
Online ISBN: 978-3-642-93383-7
eBook Packages: Springer Book Archive